Tomoki Taniguchi

Gifu-shi, 5011194, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 61 publications

Recurrent Invasive Clear Cell Subtype of Upper Tract Urothelial Carcinoma Responding to Enfortumab Vedotin and Pembrolizumab After Chemotherapy: A Case Report.

Recurrent Invasive Clear Cell Subtype of Upper Tract Urothelial Carcinoma Responding to Enfortumab Vedotin and Pembrolizumab After Chemotherapy: A Case Report.

Journal: Archivos espanoles de urologia

Published: August 17, 2026

Reply to the Letter to the Editor Regarding "Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study".

Reply to the Letter to the Editor Regarding "Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study".

Journal: Neurourology and urodynamics

Published: June 20, 2026

Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study.

Age and Nocturnal Polyuria in Nocturia: A Multicenter Voiding Diary Cohort Study.

Journal: Neurourology and urodynamics

Published: April 01, 2026

Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy.

Combination of baseline and first-week neutrophil-to-lymphocyte ratio predicts overall survival in advanced renal cell carcinoma treated with first-line combination immunotherapy.

Journal: International journal of clinical oncology

Published: February 20, 2026

Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study.

Real-World Occurrence of Adverse Events Associated With Adjuvant Pembrolizumab Therapy for Renal Cell Carcinoma: A Multicenter Retrospective Study.

Journal: International journal of urology : official journal of the Japanese Urological Association

Published: February 17, 2026

Bladder sarcomatoid carcinoma and giant cell carcinoma without recurrence after robot-assisted radical cystectomy: A case report.

Bladder sarcomatoid carcinoma and giant cell carcinoma without recurrence after robot-assisted radical cystectomy: A case report.

Journal: Urology case reports

Published: January 24, 2026

Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.

Secondary primary tumors following iodine-125 low-dose-rate brachytherapy for localized prostate cancer.

Journal: International journal of clinical oncology

Published: January 21, 2026

Renal outcomes in ANCA-associated vasculitis without clinically apparent kidney involvement: a multicentre REVEAL cohort study.

Renal outcomes in ANCA-associated vasculitis without clinically apparent kidney involvement: a multicentre REVEAL cohort study.

Journal: Rheumatology (Oxford, England)

Published: November 17, 2025

Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study.

Rituximab versus intravenous cyclophosphamide for anti-neutrophil cytoplasmic antibody-associated vasculitis with severe renal impairment: A multicentre REVEAL cohort study.

Journal: Modern rheumatology

Published: October 17, 2025

Refractory SIAD Triggered by Herpes Zoster Ophthalmicus: Impact of Postherpetic Neuralgia on Hyponatremia Duration and the Role of Tolvaptan.

Refractory SIAD Triggered by Herpes Zoster Ophthalmicus: Impact of Postherpetic Neuralgia on Hyponatremia Duration and the Role of Tolvaptan.

Journal: Internal medicine (Tokyo, Japan)

Published: October 01, 2025

Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort study.

Long-term efficacy of rituximab versus intravenous cyclophosphamide for severe ANCA-associated vasculitis in multicenter REVEAL cohort study.

Journal: Journal of internal medicine

Published: September 22, 2025

Combination immunotherapy in Japanese patients with advanced renal cell carcinoma: bridging gaps between clinical trials, real-world evidence, and the potential value of adverse events-a narrative review.

Combination immunotherapy in Japanese patients with advanced renal cell carcinoma: bridging gaps between clinical trials, real-world evidence, and the potential value of adverse events-a narrative review.

Journal: Translational cancer research

Published: August 25, 2025

Showing 1-12 of 61

Last Updated: 09/26/2026